Skip to main content

Regorafenib in Treating Patients with Previously Treated, Metastatic, or Locally Advanced Angiosarcoma

Trial Status: Closed to Accrual

This phase II trial studies regorafenib in treating patients with previously treated angiosarcoma that has spread to other places in the body (metastatic) or spread from where it started to nearby tissue or lymph nodes (locally advanced). Regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Inclusion Criteria

  • Life expectancy of at least 4 months
  • Histologically confirmed angiosarcoma
  • Tumor deemed unresectable or metastatic
  • Measurable disease per RECIST v 1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
  • Progressive disease under last palliative therapy with a history of prior ifosfamide, doxorubicin or taxane therapy for angiosarcoma; up to 4 prior therapies are allowed
  • All acute toxic effects of any prior treatment have resolved to grade 1 or less (by National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] v 4.0) at the time of registration; NOTE: exceptions to this criterion will include alopecia and fatigue
  • Total bilirubin =< 1.5 x the upper limits of normal (ULN)
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
  • Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
  • Lipase =< 1.5 x the ULN
  • Serum creatinine =< 1.5 x the ULN
  • Prothrombin time (PT)/international normalized ratio (INR) =< 1.5 x ULN
  • Platelet count >= 100000/mm^3
  • Hemoglobin >= 9 g/dL
  • Absolute neutrophil count > 1500/mm^3
  • If baseline urine protein creatinine (UPC) >= 1, a 24-hour urine protein must be assessed; patients must have a 24-hour urine protein value < grade 3 (> 3.5 g/24 hours) to be eligible
  • NOTE: subjects may not have had a transfusion within 7 days of screening assessment; NOTE: patients who are prophylactically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists; close monitoring of at least weekly evaluations will be performed until PT/INR is stable based on a measurement that is pre-dose as defined by the local standard of care
  • Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as age >= 50 years and no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test
  • Subjects (men and women) of childbearing potential must agree to use adequate contraception beginning at registration until at least 3 months after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator
  • Subject must be able to swallow and retain oral medication
  • Subjects must be able to understand and be willing to sign the written informed consent form; a signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure

Exclusion Criteria

  • Uncontrolled hypertension (systolic pressure > 140 mmHg or diastolic pressure > 90 mmHg on repeated measurement) despite optimal medical management
  • Active or clinically significant cardiac disease including: * Congestive heart failure – New York Heart Association > class II * Active coronary artery disease * Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin * Unstable angina (anginal symptoms at rest), new-onset angina within 3 months before registration, or myocardial infarction within 6 months before registration
  • Evidence or history of bleeding diathesis or coagulopathy
  • Any hemorrhage or bleeding event >= grade 3 within 4 weeks prior to registration
  • Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months of informed consent; Note: subjects with recent deep vein thrombosis (DVT) who have been treated with therapeutic anticoagulating agents for at least 6 weeks prior to study treatment are eligible
  • Subjects with any previously untreated or concurrent cancer unrelated to angiosarcoma; NOTE: exceptions include cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor; subjects surviving a cancer that was curatively treated and without evidence of disease for more than 3 years before registration are allowed; all treatments must have been completed at least 3 years prior to registration
  • Patients with pheochromocytoma
  • Patients with severe hepatic impairment (Child-Pugh class C)
  • Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
  • Ongoing infection > grade 2
  • Evidence of significant central nervous system disease including seizure disorder requiring medication, symptomatic metastatic brain or meningeal tumors
  • Presence of a non-healing wound, non-healing ulcer, or bone fracture
  • Renal failure requiring hemo-or peritoneal dialysis
  • Dehydration > grade 1
  • Interstitial lung disease with ongoing signs and symptoms at the time of registration
  • Pleural effusion or ascites that causes respiratory compromise (>= grade 2 dyspnea)
  • History of organ allograft (including corneal transplant)
  • Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
  • Any malabsorption condition
  • Evidence of abdominal fistula, gastrointestinal (GI) perforation or intraabdominal abscess
  • Women who are pregnant or breast-feeding
  • Concurrent anti-cancer therapy (chemotherapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than study treatment (regorafenib)
  • Prior use of regorafenib
  • Prior use of sorafenib
  • Use of cytotoxic chemotherapy within 21 days of registration
  • Use of targeted therapy within two half-lives of registration
  • Radiation directed at target lesion within 28 days of registration
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before registration
  • Therapeutic anticoagulation with vitamin-K antagonists (e.g., warfarin) or with heparins and heparinoids; NOTE: Prophylactic anticoagulation as described below is allowed: * Low dose warfarin (1 mg orally, once daily) with prothrombin time PT-INR =< 1.5 x ULN is permitted; subjects taking concomitant warfarin should be monitored regularly for changes in PT, PT-INR or clinical bleeding episodes * Low dose aspirin (=< 100 mg daily) * Prophylactic doses of heparin
  • Any condition which, in the investigator’s opinion, makes the subject unsuitable for trial participation
  • Substance abuse, medical, psychological or social conditions that may interfere with the subject’s participation in the study or evaluation of the study results
  • Unable or unwilling to discontinue use of strong inducers and inhibitors of CYP450 for at least 14 days prior to the first dose of study treatment and for the duration of the study; CYP3A4 substrates can be administered, but investigators will need to be aware of possible increased or decreased effectiveness of the non-study drug and this should be recorded in concomitant medications; BCRP and PgP inducers and inhibitors should be used with caution if another alternative drug is not able to be used; Note: as this list is constantly evolving, if a medication is incorrectly documented as prohibited in this protocol, documentation from the site pharmacist to the contrary will be acceptable for the purposes of registration


Santa Monica
Sarcoma Oncology Center
Contact: Sant Prakashmir Chawla
Phone: 310-552-9999


Mayo Clinic in Florida
Contact: Steven Attia
Phone: 904-953-2558


Northwestern University
Contact: Mark Agulnik
Phone: 312-695-1222


Iowa City
University of Iowa / Holden Comprehensive Cancer Center
Contact: Mohammed M. Milhem
Phone: 319-356-2324


Mayo Clinic in Rochester
Contact: Scott H. Okuno
Phone: 507-284-4849


Saint Louis
Washington University School of Medicine
Contact: Brian Andrew Van Tine
Phone: 314-747-8475


I. To define the progression-free survival (PFS) at 4 months with daily oral regorafenib (160 mg) in previously treated locally advanced/metastatic angiosarcoma patients.


I. Progression-free rate at 3 and 6 months.

II. Progression-free survival.

III. Overall survival (up to 5 years).

IV. Response rate (by Response Evaluation Criteria in Solid Tumors [RECIST] version [v] 1.1).

V. Rate and duration of tumor control (complete response [CR] + partial response [PR] + stable disease [SD]).

VI. Safety/tolerability of regorafenib.


Patients receive regorafenib orally (PO) once daily (QD) on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 6 months for up to 5 years.

Trial Phase Phase II

Trial Type Treatment

Lead Organization
Northwestern University

Principal Investigator
Mark Agulnik

  • Primary ID NU 13S02
  • Secondary IDs NCI-2013-02278, STU00087654, ONC-2013-129
  • ID NCT02048722